COHERUS BIOSCIENCES INC. - COMMON STOCK

Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal

21 Jan 2024 22:15:00 By Nasdaq GlobeNewswire

Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium

18 Jan 2024 13:05:00 By Nasdaq GlobeNewswire

Coherus BioSciences Management to Present at the 42nd Annual J.P. Morgan Healthcare Conference

03 Jan 2024 06:00:00 By Nasdaq GlobeNewswire

Coherus Announces U.S. Launch of LOQTORZI™

02 Jan 2024 05:29:00 By Nasdaq GlobeNewswire

Coherus Announces FDA Approval of UDENYCA ONBODY™, a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv

26 Dec 2023 13:01:00 By Nasdaq GlobeNewswire

Coherus Announces Updated NCCN Clinical Practice Guidelines Positioning LOQTORZI™ (toripalimab-tpzi) as Preferred Category 1 Regimen for First-Line Treatment of Cancer of the Nasopharynx

11 Dec 2023 05:30:00 By Nasdaq GlobeNewswire

Coherus BioSciences Announces CFO Transition Plans

07 Dec 2023 14:55:48 By Nasdaq GlobeNewswire

Coherus Presents Phase 1/2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2023 ESMO Immuno-Oncology Congress

06 Dec 2023 01:00:00 By Nasdaq GlobeNewswire

Coherus and Junshi Biosciences Announce Publication of Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Trial Evaluating LOQTORZI™ (toripalimab-tpzi) as Treatment for Nasopharyngeal Carcinoma, in the Journal of the American Medical Association

28 Nov 2023 08:16:23 By Nasdaq GlobeNewswire

Coherus BioSciences Reports Third Quarter 2023 Financial Results and Business Highlights

06 Nov 2023 13:07:41 By Nasdaq GlobeNewswire

Coherus Presents Data from Next-generation Immuno-oncology Programs at 38th Annual Meeting of Society for Immunotherapy of Cancer (SITC)

03 Nov 2023 05:30:00 By Nasdaq GlobeNewswire

Coherus BioSciences to Participate at Upcoming November Investor Conferences

02 Nov 2023 17:00:08 By Nasdaq GlobeNewswire

Coherus BioSciences to Report Third Quarter 2023 Financial Results on November 6, 2023

30 Oct 2023 15:00:00 By Nasdaq GlobeNewswire

Coherus and Junshi Biosciences Announce FDA Approval of LOQTORZI™ (toripalimab-tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)

27 Oct 2023 12:07:20 By Nasdaq GlobeNewswire

Coherus BioSciences Announces New Employment Inducement Grants

24 Oct 2023 16:41:27 By Nasdaq GlobeNewswire

Coherus Announces Toripalimab Data at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

14 Oct 2023 09:30:00 By Nasdaq GlobeNewswire

Coherus Announces Resubmission of Biologics License Application (BLA) Supplement for UDENYCA® ONBODY™

05 Oct 2023 05:30:00 By Nasdaq GlobeNewswire

CIMERLI® (ranibizumab-eqrn) Sales Exceed 100,000 Doses in First Year of Launch

04 Oct 2023 05:30:00 By Nasdaq GlobeNewswire

Coherus Applauds Congressional Designation of September 30th as Rare Cancer Day

02 Oct 2023 06:00:00 By Nasdaq GlobeNewswire

Coherus Announces Three Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

27 Sep 2023 06:10:29 By Nasdaq GlobeNewswire